Efficacy of Lactobacillus reuteri Supplementation in Eradication of H. pylori: A Comparison Study with Triple Drug Therapy
Kumar Parth, Ramakrishna Prudhivi, Sujatha Palatheeya, Syed Kamran Abbas, K. Varsha, B. V. Niharika, Banaijingkmen Lyngkhoi
Journal of Pharmaceutical Research International · pp. 151–159 · Published 1 Dec 2021
10.9734/jpri/2021/v33i52B33611Abstract
Helicobacter pylori (H. pylori) infections affect roughly one-half of the world’s population. Although many standard regimens, including triple-drug therapy, eradicate H. pylori, the success rate and efficacy have been declining due to associated side effects and symptom severity. The addition of probiotics to a standard regimen can considerably increase eradication rates. The objective is to find the efficacy of a probiotic Lactobacillus reuteri (L. reuteri) in eradicating human H. pylori infection and effect on symptoms regression and side effects associated with triple therapy. This prospective interventional study was conducted in 90 H. pylori-positive patients. 45 patients received standard triple treatment (group-I) for 14 days. Another 45 patients received a combination of standard triple therapy and L. reuteri (group-II) for 14 days. After the completion of treatment, H. pylori status was evaluated using a 13-C Urea-Breath Test (UBT). Each subject is interviewed with a validated Gastrointestinal Symptoms Rating Scale (GSRS) questionnaire to record symptoms and symptom severity before and after the therapy. Group-II patients showed a significantly higher eradication rate (86.67%) than group-I patients (66.67%). The absolute values of 13C-UBT (group-I: 14.02± 5.4, group-II: 11.9±3.73) revealed that a more substantial reduction in H. Pylori load was observed in group II. Statistical analysis proved that group II patients had a significant reduction in GSRS mean scores (baseline score: 15.39±4.52 to end score: 5.33±2.34) compared to group-I patients (baseline score: 14.47±3.67 to end score: 9.86±4.78). Addition of L. reuteri has reduced side effects associated with triple drug therapy except bloating. In conclusion, supplementation of L. reuteri to standard triple drug therapy significantly improved the eradication rate of H. pylori, reduced intensity of gastrointestinal symptoms and also treatment related side effects.
Cited by 15
A. Hinduja · EMJ Gastroenterology · 2023
Showing 11 of 15 known citations — external sources report more than can currently be individually listed.
Related research
- No Association between Helicobacter Pylori Infection and Type 2 Diabetes Mellitus; A Case-control Study in the North-Western Part of Ghana — shares topic coverage
- Protection against Helicobacter pylori Infection in BALB/c Mice by Oral or Intramuscular Administration of Multicomponent Vaccine of rCagA +LPS +CpG — shares topic coverage
- Burden of Helicobacter pylori Infections and Associated Risk Factors among Cases of Iron Deficiency Anaemia in Egypt — shares topic coverage
- Impact of Dietary Behavior, Lifestyle & Socioeconomic Status on Patients Infected with H. pylori — shares topic coverage
- Anti-urease Activity of Mimusops elengi Linn (Sapotaceae) — shares topic coverage
Article metrics
Real usage data collected on this platform.
2
Page views
0
PDF downloads
0
Outbound clicks
15
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.